Experimental drug AB-218 tested in brain tumor patients
NCT ID NCT05577416
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called AB-218 (safusidenib) in 14 adults with a specific type of slow-growing brain tumor (IDH1 mutated low grade glioma) who were already scheduled for surgery. The goal was to see if it's possible to measure how much drug gets into the tumor and to check for safety. Participants took the drug for 28 days before surgery, and some continued afterward to monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Safusidenib Erbumine (AB-218)
What this could lead to
If successful, this could help determine whether AB-218 reaches brain tumors effectively and is safe, potentially leading to a new treatment option for IDH1 mutated low grade glioma.
What could go wrong
This is an early-phase trial with only 14 participants, so results may not apply to all patients. The drug may not show enough benefit or could cause side effects, and further larger studies are needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Royal Melbourne Hospital
Melbourne, Victoria, Australia